Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
J Virol. 2013 Mar;87(6):3284-94. doi: 10.1128/JVI.02576-12. Epub 2013 Jan 9.
Hendra virus (HeV) and Nipah virus (NiV) are deadly zoonotic viruses for which no vaccines or therapeutics are licensed for human use. Henipavirus infection causes severe respiratory illness and encephalitis. Although the exact route of transmission in human is unknown, epidemiological studies and in vivo studies suggest that the respiratory tract is important for virus replication. However, the target cells in the respiratory tract are unknown, as are the mechanisms by which henipaviruses can cause disease. In this study, we characterized henipavirus pathogenesis using primary cells derived from the human respiratory tract. The growth kinetics of NiV-Malaysia, NiV-Bangladesh, and HeV were determined in bronchial/tracheal epithelial cells (NHBE) and small airway epithelial cells (SAEC). In addition, host responses to infection were assessed by gene expression analysis and immunoassays. Viruses replicated efficiently in both cell types and induced large syncytia. The host response to henipavirus infection in NHBE and SAEC highlighted a difference in the inflammatory response between HeV and NiV strains as well as intrinsic differences in the ability to mount an inflammatory response between NHBE and SAEC. These responses were highest during HeV infection in SAEC, as characterized by the levels of key cytokines (interleukin 6 [IL-6], IL-8, IL-1α, monocyte chemoattractant protein 1 [MCP-1], and colony-stimulating factors) responsible for immune cell recruitment. Finally, we identified virus strain-dependent variability in type I interferon antagonism in NHBE and SAEC: NiV-Malaysia counteracted this pathway more efficiently than NiV-Bangladesh and HeV. These results provide crucial new information in the understanding of henipavirus pathogenesis in the human respiratory tract at an early stage of infection.
亨德拉病毒(HeV)和尼帕病毒(NiV)是致命的人畜共患病病毒,目前尚无获准用于人类的疫苗或疗法。亨尼帕病毒感染可导致严重的呼吸道疾病和脑炎。尽管人类感染的确切途径尚不清楚,但流行病学研究和体内研究表明,呼吸道对于病毒复制很重要。然而,呼吸道中的靶细胞以及亨尼帕病毒如何引起疾病的机制尚不清楚。在这项研究中,我们使用源自人类呼吸道的原代细胞来表征亨尼帕病毒的发病机制。在支气管/气管上皮细胞(NHBE)和小气道上皮细胞(SAEC)中测定了 NiV-Malaysia、NiV-Bangladesh 和 HeV 的生长动力学。此外,还通过基因表达分析和免疫测定评估了宿主对感染的反应。病毒在这两种细胞类型中均有效复制,并诱导形成大的合胞体。NHBE 和 SAEC 中对亨尼帕病毒感染的宿主反应突出了 HeV 和 NiV 株之间炎症反应的差异,以及 NHBE 和 SAEC 之间引发炎症反应的内在能力差异。这些反应在 SAEC 中感染 HeV 时最高,其特征是负责免疫细胞募集的关键细胞因子(白细胞介素 6 [IL-6]、IL-8、IL-1α、单核细胞趋化蛋白 1 [MCP-1] 和集落刺激因子)的水平最高。最后,我们在 NHBE 和 SAEC 中鉴定了病毒株依赖性的 I 型干扰素拮抗作用的可变性:NiV-Malaysia 比 NiV-Bangladesh 和 HeV 更有效地拮抗该途径。这些结果在感染早期提供了有关亨尼帕病毒在人类呼吸道发病机制的重要新信息。